Trial Profile
Use of Nebulized Fentanyl in Patients With Mild-to-Moderate Interstitial Lung Disease and Chronic Dyspnea
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Fentanyl (Primary)
- Indications Dyspnoea; Interstitial lung diseases
- Focus Therapeutic Use
- 21 Apr 2022 Status changed from suspended to completed.
- 15 Sep 2020 Planned End Date changed from 1 Aug 2020 to 1 Aug 2022.
- 15 Sep 2020 Status changed from active, no longer recruiting to suspended.